ZYME
Zymeworks Inc

2,596
Mkt Cap
$1.76B
Volume
152,492.00
52W High
$28.49
52W Low
$9.03
PE Ratio
-27.50
ZYME Fundamentals
Price
$23.29
Prev Close
$23.81
Open
$23.30
50D MA
$24.10
Beta
0.91
Avg. Volume
970,910.05
EPS (Annual)
-$1.62
P/B
5.51
Rev/Employee
$266,797.20
$903.13
Loading...
Loading...
News
all
press releases
Zymeworks Q4 Earnings Call Highlights
Zymeworks (NASDAQ:ZYME) executives used the company's fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidatamab, outline a new royalty-backed...
MarketBeat·1h ago
News Placeholder
More News
News Placeholder
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -58.64% and -88.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4h ago
News Placeholder
Zymeworks (NASDAQ:ZYME) Releases Earnings Results, Misses Estimates By $0.20 EPS
Zymeworks (NASDAQ:ZYME - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.20...
MarketBeat·4h ago
News Placeholder
Zymeworks Inc. Q4 Loss Widens
(RTTNews) - Zymeworks Inc. (ZYME) announced Loss for its fourth quarter of -$41.209 million...
Nasdaq News: Markets·5h ago
News Placeholder
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma
(RTTNews) - Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX), a buyer of...
Nasdaq News: Markets·5h ago
News Placeholder
Earnings Breakdown: Zymeworks Q4
read more...
Benzinga·6h ago
News Placeholder
A Look Ahead: Zymeworks's Earnings Forecast
read more...
Benzinga·3d ago
News Placeholder
Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +7.80% and +1.21%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
Key PointsRedmile Group sold 3,214,096 ZYME shares, estimated at $70.10 million based on quarterly average prices...
Nasdaq News: Markets·8d ago
News Placeholder
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Zymeworks Inc. (NASDAQ:ZYME - Get Free Report) have been given an average recommendation of "Buy" by the seven research firms that are currently covering the company, Marketbeat reports...
MarketBeat·23d ago
<
1
2
...
>

Latest ZYME News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.